Ferring Acthrel to be launched in mid-summer; orphan drug is company's first U.S. approval.
Executive Summary
FERRING ACTHREL DIAGNOSTIC TO BE LAUNCHED IN MID-SUMMER at an expected cost of $275 per treatment (one 100 mcg vial), the company said. Corticorelin ovine triflutate for injection was approved May 23 for "use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome." The orphan indication covers approximately 63,000 patients per year, Ferring said.